Veracyte (VCYT) Liabilities and Shareholders Equity (2016 - 2025)
Veracyte's Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $1.4 billion for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 8.15% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $5.4 billion, up 8.46%, while the annual FY2025 figure was $1.4 billion, 8.15% up from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $1.4 billion at Veracyte, up from $1.4 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q4 2025 and bottomed at $1.0 billion in Q1 2021.
- The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2021), against an average of $1.2 billion.
- The largest annual shift saw Liabilities and Shareholders Equity surged 300.19% in 2021 before it dropped 5.09% in 2022.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.2 billion in 2021, then dropped by 2.64% to $1.2 billion in 2022, then dropped by 3.59% to $1.1 billion in 2023, then increased by 16.6% to $1.3 billion in 2024, then grew by 8.15% to $1.4 billion in 2025.
- Per Business Quant, the three most recent readings for VCYT's Liabilities and Shareholders Equity are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025).